The Wall Street Journal reports that researchers at Johns Hopkins are concerned about potential safety issues with the drug Avastin, which is sometimes proscribed on an off-label basis to macular degeneration patients. A study comparing Avastin to its leading competition Lucentis (which was formulated specifically for the eye condition) found that those taking Avastin had an 11 percent higher mortality risk and 57 percent higher risk of cerebral hemorrhage. The study did not take into account other risk factors like smoking, hypertension, or elevated cholesterol levels. Source: Wall Street Journal
At Natural Eye Care we offer people with macular degeneration options that include nutrition advice, lifestyle recommendations, and natural supplement suggestions.